WO2025003978 - DEVICE AND METHODS FOR ADMINISTERING A THERAPEUTIC COMPOSITION TO THE PHARYNGEAL MUSCLE
National phase entry:
Publication Number
WO/2025/003978
Publication Date
02.01.2025
International Application No.
PCT/IB2024/056310
International Filing Date
28.06.2024
Title **
[English]
DEVICE AND METHODS FOR ADMINISTERING A THERAPEUTIC COMPOSITION TO THE PHARYNGEAL MUSCLE
[French]
DISPOSITIF ET PROCÉDÉS D'ADMINISTRATION D'UNE COMPOSITION THÉRAPEUTIQUE AU MUSCLE PHARYNGÉ
Applicants **
BENITEC IP HOLDINGS INC.
Corporation Trust Centre, 1209 Orange Street
City of Wilmington, Delaware 19801, US
Inventors
MUKADAM, Sophie
c/o Benitec Biopharma Inc.
3940 Trust Way
Hayward, California 94545, US
BANKS, Jerel
c/o Benitec Biopharma Inc.
3940 Trust Way
Hayward, California 94545, US
ST-GUILY, Jean Lacau
c/o Benitec Biopharma Inc.
3940 Trust Way
Hayward, California 94545, US
Priority Data
63/510,750
28.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP Australia
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3049 | |
| EPO | Filing, Examination | 33454 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 15310 |
Total: 52975 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to devices and methods for administration of a therapeutic composition to the pharyngeal muscle. In particular, the devices and methods of the disclosure may be used in treatment or prevention of dysphagia, including dysphagia associated with oculopharyngeal muscular dystrophy (OPMD) in individuals suffering therefrom or predisposed thereto. Additionally, the present disclosure relates to devices and methods used to deliver modified adeno-associated virus (AAV) delivery vectors comprising 'silence and replace' DNA constructs, including compositions comprising same.[French]
La présente divulgation concerne des dispositifs et des procédés d'administration d'une composition thérapeutique au muscle pharyngé. En particulier, les dispositifs et les procédés de la divulgation peuvent être utilisés dans le traitement ou la prévention de la dysphagie, notamment la dysphagie associée à la dystrophie musculaire oculopharyngée (OPMD), chez des individus atteints de celle-ci ou prédisposés à celle-ci. De plus, la présente divulgation concerne des dispositifs et des procédés utilisés pour administrer des vecteurs d'administration de virus adéno-associé (AAV) modifiés comprenant des constructions d'ADN « silence et remplacement », notamment des compositions les comprenant.